Abstract
We sought to explore whether trimetazidine addition reduces QT dispersion early after acute myocardial infarction. Prospectively, we randomized 60 consecutive patients with first acute ST elevation myocardial infarction to receive either trimetazidine 20 mg tid (trimetazidine group 30 patients), or placebo (placebo group 30 patients). QT dispersion and corrected QT dispersion were measured on day 3 and day 7 of admission. Patients were followed during hospitalization for the occurrence of ventricular arrhythmias (sustained ventricular tachycardia or ventricular fibrillation). QT dispersion and corrected QT dispersion were significantly lower in trimetazidine group in both days, compared to control group: day 3, 58±5 msec versus 78±6 msec, and 69±11 msec versus 91±10 msec, respectively, p < 0.001 for both; day 7, 41±7 msec versus 60±8 msec, and 47±9 msec versus 69±6 msec, respectively, p < 0.0001 for both. This finding was consistent in all prespecified subgroups. During hospital stay, 3 patients (10%) of the placebo group developed sustained ventricular tachycardia and 2 (6.6%) died of ventricular fibrillation, but no one in the trimetazidine group had such arrhythmias. Conclusion: In patients with first acute myocardial infarction, the addition of trimetazidine significantly reduced both QT dispersion and corrected QT dispersion and reduced the occurrence of ventricular arrhythmias throughout hospitalization.
Keywords: Trimetazidine, QT dispersion, myocardial infarction
Current Drug Therapy
Title: Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?
Volume: 4 Issue: 1
Author(s): Khaled El-Meniawy, Hanan Hafez, Hala Bamatraf and Wail Nammas
Affiliation:
Keywords: Trimetazidine, QT dispersion, myocardial infarction
Abstract: We sought to explore whether trimetazidine addition reduces QT dispersion early after acute myocardial infarction. Prospectively, we randomized 60 consecutive patients with first acute ST elevation myocardial infarction to receive either trimetazidine 20 mg tid (trimetazidine group 30 patients), or placebo (placebo group 30 patients). QT dispersion and corrected QT dispersion were measured on day 3 and day 7 of admission. Patients were followed during hospitalization for the occurrence of ventricular arrhythmias (sustained ventricular tachycardia or ventricular fibrillation). QT dispersion and corrected QT dispersion were significantly lower in trimetazidine group in both days, compared to control group: day 3, 58±5 msec versus 78±6 msec, and 69±11 msec versus 91±10 msec, respectively, p < 0.001 for both; day 7, 41±7 msec versus 60±8 msec, and 47±9 msec versus 69±6 msec, respectively, p < 0.0001 for both. This finding was consistent in all prespecified subgroups. During hospital stay, 3 patients (10%) of the placebo group developed sustained ventricular tachycardia and 2 (6.6%) died of ventricular fibrillation, but no one in the trimetazidine group had such arrhythmias. Conclusion: In patients with first acute myocardial infarction, the addition of trimetazidine significantly reduced both QT dispersion and corrected QT dispersion and reduced the occurrence of ventricular arrhythmias throughout hospitalization.
Export Options
About this article
Cite this article as:
El-Meniawy Khaled, Hafez Hanan, Bamatraf Hala and Nammas Wail, Trimetazidine: Does it Actually Reduce QT Dispersion After First Acute Myocardial Infarction?, Current Drug Therapy 2009; 4 (1) . https://dx.doi.org/10.2174/157488509787081822
DOI https://dx.doi.org/10.2174/157488509787081822 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNAs: Novel Diagnostic and Prognostic Biomarkers in Atherosclerosis
Current Topics in Medicinal Chemistry Small Heat Shock Proteins and Protein-Misfolding Diseases
Current Pharmaceutical Biotechnology Mitochondrial Involvement in Psychiatric Illness in Adults
Current Psychiatry Reviews Out-of-Hospital Cardiac Arrest –Optimal Management
Current Cardiology Reviews Prevention of Sudden Cardiac Death in Hemodialysis Patients
Cardiovascular & Hematological Disorders-Drug Targets Strain Imaging Echocardiography: What Imaging Cardiologists Should Know
Current Cardiology Reviews Vascular Endothelial Growth Factor: A New Paradigm for Targeting Various Diseases
Current Angiogenesis (Discontinued) Study of Parasitic Infections, Cancer, and other Diseases with Mass-Spectrometry and Quantitative Proteome-Disease Relationships
Current Proteomics microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Gene Therapy Strategies to Prevent Autoimmune Disorders
Current Gene Therapy Donor-transmitted Anterior Myocardial Ischaemia in a Teenager: How to Proceed?
New Emirates Medical Journal The Use of Exercise Echocardiography in the Evaluation of Mitral Regurgitation
Current Cardiology Reviews Human Induced Pluripotent Stem Cells for Inherited Cardiovascular Diseases Modeling
Current Stem Cell Research & Therapy Efficacy and Safety of Mesenchymal Stem Cell Therapy in Patients with Acute Myocardial Infarction: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Current Stem Cell Research & Therapy S-nitrosation/Denitrosation in Cardiovascular Pathologies: Facts and Concepts for the Rational Design of S-nitrosothiols
Current Pharmaceutical Design Gene Therapy Approaches for Cardiovascular Diseases
Current Gene Therapy Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation
Current Vascular Pharmacology Targeted Gene Deletion of Prolyl Hydroxylase Domain Protein 3 Triggers Angiogenesis and Preserves Cardiac Function by Stabilizing Hypoxia Inducible Factor 1 Alpha Following Myocardial Infarction
Current Pharmaceutical Design Cardiovascular Complications in Diabetes: Lessons from Animal Models
Current Medicinal Chemistry Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets